

# Verona Pharma

02:04 09 Mar 2012

## Verona Pharma to start clinical trials on COPD drug in UK within months

Respiratory disease specialists Verona Pharma (LON:VRP) plans to start clinical trials of its drug RPL554 to treat COPD within the next couple of months, it said.

The company has contracted the Medicines Evaluation Unit in Manchester to carry out the phase II anti-inflammatory trial - the first study in the UK.

The enrollment of patients is to start in the second quarter and the preliminary results are expected early in Q4 this year, the company said.

COPD or chronic obstructive pulmonary disease causes a narrowing of the airways in the lungs, causing shortness of breath.

The trial, being led by Professor Dave Singh, will see healthy volunteers having their airways exposed to an inflammatory stimulus.

They will then be treated using six repeated daily doses of RPL554 with an inhaler, with the primary endpoint being the reduction of inflammation.

Verona's chief executive Michael Walker said: "The fundraising completed in January this year has enabled us to initiate this important trial to show that RPL554 is anti-inflammatory.

"We have already demonstrated that this drug is a bronchodilator, i.e. dilates the airways, enabling patients to breathe more easily. If we can demonstrate there is also a combined anti-inflammatory action, this would place RPL554 in a completely new class of therapy for COPD and asthma sufferers."


He added: "Our objective continues to be to appoint a partner to develop RPL554 into a marketed medicine. The results from this trial will provide further useful and important data for this purpose".

This clinical trial follows earlier work to test the anti-inflammatory actions of RPL554, including preclinical studies and a pilot nasal study in humans performed as part of the initial Phase I/IIa clinical trial of the drug, the company added.

**Price:** 49.5

**Market Cap:** £52.71 m

### 1 Year Share Price Graph



### Share Information

**Code:** VRP

**Listing:** AIM

<b>52 week</b>	<b>High</b>	<b>Low</b>
	102	28.6

**Sector:** Pharma & Biotech

**Website:** [www.veronapharma.com](http://www.veronapharma.com)

### Company Synopsis:

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).